Mayo Clinic challenges some recommendations in updated cholesterol treatment guideline

Once again we have some of the most brilliant minds in medicine  not willing to change from the status quo of cholesterol is bad.  The real problem is inflammation which grabs the cholesterol particles as they float by. Thus this cholesterol lowering is a secondary prevention option. If they would focus on solving the real problem of inflammation we wouldn't need all these statins that just disrupt our normal funtions. Our brain is composed of a fair amount of cholesterol. This table from here explains how much cholesterol.
http://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0CCQQFjAA&url=http%3A%2F%2Fwww.jlr.org%2Fcontent%2F6%2F4%2F537.full.pdf&ei=h7jsU5GyHoqcyAScu4CYAw&usg=AFQjCNHzTR0vtSCnvnCE3PwFSgmvhc6yLQ&sig2=NMQy6qWbum6T_7o40WBqGA&bvm=bv.72938740,d.aWw

Do we really want to disrupt our brains that much by compromising our  cholesterol levels?
Do NOT listen to anything I have to say, It is the rantings of a stroke addled brain, but I bet your doctor will not be able to easily refute the findings. 
And here are the Mayo recommendations:
http://medicalxpress.com/news/2014-08-mayo-clinic-cholesterol-treatment-guideline.html
A few selected paragraphs;
Mayo's cholesterol treatment recommendations challenge some core ACC/AHA recommendations, and go further in-depth in some areas. For example:
* The ACC/AHA cholesterol treatment guideline recommends prescribing the strongest statins at high doses to most men older than 65, even those with no history of heart disease, or any major risk factor for heart attacks, and with normal cholesterol levels. Men this age will be classified as high risk only on the basis of age. The Mayo task force found no evidence from clinical trials to recommend treating people only on the basis of age in the absence of risk factors, high cholesterol or inflammation.
This is fascinating considering this guideline; Which this seems to go against.

FDA announces new safety recommendations for high-dose simvastatin

* The ACC/AHA cholesterol treatment guideline recommends cholesterol-lowering medication as a primary preventive measure against cardiovascular disease, and encourages health care providers to simultaneously emphasize the importance of healthy lifestyle habits. The Mayo task force encourages lifestyle changes—such as exercise and dietary changes—first, followed by re-evaluating risk in three to six months before prescribing statins, especially in motivated patients and with borderline high risk.
* The ACC/AHA cholesterol treatment guideline recommends statins for all people with diabetes mellitus who are 40 years or older. The Mayo task force debunks the concept that all diabetics have the same risk as people with history of heart attacks. The Mayo task force does not recommend in favor of or against the use of statins in patients with diabetes in whom the risk for heart attacks or stroke is low based on the calculator proposed by the ACC/AHA.